In a mouse model of islet cell carcinoma, anti-VEGFR2 treatment was dichotomized into early- versus late-stage response.167 Initial regions of hypoxia induced by VEGFR2 blockade were circumvented by tumor cell expression of other angiogenic factors such as FGF. The gene discussed is KDR; the disease is neoplasm.